CLINICAL TRIALS PROFILE FOR TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE
✉ Email this page to a colleague
All Clinical Trials for tipiracil hydrochloride; trifluridine
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01955837 ↗ | Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia | Completed | Taiho Pharmaceutical Co., Ltd. | Phase 3 | 2013-09-01 | To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies. |
NCT02654639 ↗ | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | Terminated | Georgetown University | Phase 2 | 2016-02-01 | Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC |
NCT03278106 ↗ | TAS-102 in Treating Advanced Biliary Tract Cancers | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2017-10-20 | This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
NCT03278106 ↗ | TAS-102 in Treating Advanced Biliary Tract Cancers | Active, not recruiting | Mayo Clinic | Phase 2 | 2017-10-20 | This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tipiracil hydrochloride; trifluridine
Condition Name
Condition Name for tipiracil hydrochloride; trifluridine | |
Intervention | Trials |
Metastatic Colorectal Cancer | 12 |
Colorectal Cancer | 7 |
Stage IVC Colorectal Cancer AJCC v8 | 6 |
Stage IV Colorectal Cancer AJCC v8 | 6 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for tipiracil hydrochloride; trifluridine
Trials by Country
Clinical Trial Progress for tipiracil hydrochloride; trifluridine
Clinical Trial Phase
Clinical Trial Sponsors for tipiracil hydrochloride; trifluridine
Sponsor Name